Loading clinical trials...

RECRUITINGNA

AI-Based Mobile Intervention on Medication Non-Adherence and Transition

NCT07445074•University of Central Florida

Summary

This study aims to examine whether the AI-personalized version of the Medilepsy® app is more effective than the non-AI (standard version without AI personalization) can improve key outcomes, such as medical adherence and transition readiness, among underserved adolescents and young adults with epilepsy, ages 14-24, in Florida, USA. Outcomes are organized into primary (effectiveness), secondary (usability), and exploratory (language experience) endpoints.

Eligibility

Age

14 - 24 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosed with epilepsy
•Currently prescribed anti-seizure medicine (ASMs)
•Identified as part of an underserved population, defined as meeting at least one of the following: member of a racial or ethnic group historically underrepresented in research or healthcare or low-income status (e.g., eligible for public assistance or government-subsidized health coverage)
•Are between 14-17 years old and able to provide assent, with a parent or LAR present to receive app notifications throughout the study
•Are between 18-24 years old and able to provide informed consent
•Able to read, speak, and write in English
•Resides in Florida
•Receive outpatient medical services

Exclusion Criteria

•They do not own a mobile device with internet access.
•They have a history of severe intellectual disability.
•They are unable to operate a mobile device (keyboard or touchscreen).
•Reside in an in-patient setting.
•Adults unable to consent.
•Pregnant women (excluded because pregnancy is not relevant to the study focus).
•Prisoners.

Locations (1)

University of Central Florida

Orlando, Florida, United States

Key Dates

Start Date

March 1, 2026

Primary Completion Date

December 1, 2026

Completion Date

December 1, 2026

Last Updated

March 3, 2026

Enrollment

200

ESTIMATED participants

Conditions

EpilepsySeizure

Interventions

Medilepsy® Chatbot AI-Enhanced

OTHER

Medilepsy® Chatbot Standard

OTHER

Contacts

Michelle Tall, PhD, RN, FAES

CONTACT

4077970555 Michelle.Tall@UCF.edu

Amoy Fraser, PhD, CCRP, PMP

CONTACT

4072668742 Amoy.Fraser@UCF.edu

Thalamus Seizure Detection With a Deep Brain Stimulator System

NCT06700356

Epilepsy; Seizure

View study

RECRUITINGPHASE3

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05077904

Stereotypical Prolonged Seizures

View study

RECRUITINGPHASE3

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 3, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

AI-Based Mobile Intervention on Medication Non-Adherence and Transition

Inclusion Criteria

Exclusion Criteria

Thalamus Seizure Detection With a Deep Brain Stimulator System

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

Intracranial Investigation of Neural Circuity Underlying Human Mood

Late-Onset Seizures: Trial of Vascular Risk Investigation and Treatment